Farewell periods. Now what?
Reviewed Dr Jo Mackson, MBBS FRACGP
Published June 2026
Reading time About 28 mins, 3 to 4 mins per part
Short on time? Start with the Mini Guide, then come back here when you want the full picture.
This guide picks up after our first two, the Late Reproductive Stage and Perimenopause guides. If you are not yet 12 months past your last period, those are the guides for you. If you are, welcome to the third chapter, which covers what menopause actually is, what to expect in the years that follow, and how to think about MHT and long-term health.
Because once you understand the why, everything that follows, the symptoms, the investigations, the treatment options, starts to make sense.
Before we begin our deep dive into menopause, we need to acknowledge why you are reading this in the first place. Women’s health, and women’s hormonal health in particular, has been under-researched, over-simplified and too often dismissed, leaving most of us trying to make sense of our own bodies without the education we need to do so. That is why this Deep Dive exists. Because as women, most of us have never been taught the specific biology that shapes so much of our lives. School sex ed for most of us was a brief tour of the fallopian tubes, an introduction to pads and tampons, and the unforgettable awkwardness of a condom on a banana. Our mothers, aunties, and grandmothers were often taught even less, resulting in a knowledge gap that has been quietly handed down for generations. This stops here. So bear with us if this Deep Dive gets a bit science-heavy, and we apologise in advance for any flashbacks to the Year 8 science lab. We promise it will be worth it, because we believe knowing how the cycle that underpins your life as a woman works is far more useful than knowing how plants turn sunlight into food. Unless you are a botanist.
So yes, there will be medical terminology, the odd graph, and drug names that look like a toddler was let loose on a keyboard. Read it at your own pace. Skip ahead if you need to. Come back to the parts that matter most for you. Consider this the education that is long overdue. And don’t worry, there is no pop quiz at the end. Although if “body-identical hormones” comes up at your next trivia night, you can thank us later.
Now, before we let you loose below, a quick note about that medical terminology. If you are reading online, just toggle your mouse over the word and you can get a brief definition. If you have printed and are reading it old school, hats off to you. We have included a glossary at the end of the guide just for you.
What menopause actually is.
A single point in time.
Menopause is defined as 12 consecutive months without a menstrual period, in the absence of any other cause. That is it. It is a single point in time, confirmed in hindsight. You can only know it has happened once those 12 months have passed.
The average age in Australia is 51, with a normal range spanning roughly from 45 to 55. Around the world, the average age of menopause ranges from roughly 45 to 52, varying with ancestry, nationality, and overall health. Menopause before 45 is considered early. Before 40 it is called premature ovarian insufficiency (POI), which is a different clinical situation requiring its own approach.
When menopause comes early or suddenly.
Menopause does not always arrive slowly or on schedule. If your ovaries are removed, usually alongside a hysterectomy, it happens overnight, at whatever age the surgery takes place, and because there is no gradual wind-down the symptoms can arrive suddenly and hit harder. Early menopause, before 45, and premature ovarian insufficiency, before 40, raise the same question.
For all of these the thinking on MHT is different, and usually more straightforward. It is generally recommended at least until around 51, the age menopause would have arrived naturally, and not mainly to ease symptoms. It replaces hormones your body would still have been making, and protects your bone and cardiovascular health over the years it would otherwise have had them. This is a group too often left undertreated, so if it is you, it is worth making sure that conversation happens.
The new hormonal landscape.
What has happened hormonally is, for once, relatively straightforward. The ovaries have essentially ceased their reproductive function. Follicle recruitment has stopped. Ovulation is no longer occurring. Oestrogen and progesterone, the hormones produced by active follicles and the corpus luteum, have declined to persistently low levels. The hormonal chaos of perimenopause, the unpredictable spikes and crashes, has settled. What replaces it is a new hormonal landscape of stable, but low, levels of oestrogen and progesterone.
That stability, after years of volatility, is for many women a welcome change. The mood swings, the unpredictable cycles, the PMS that had become unmanageable, often improve. But sustained oestrogen deficiency brings its own set of consequences, some symptomatic and some silent but clinically significant over time. Understanding both is what this guide is about.
The decades that follow.
The term postmenopause refers to all the years following that 12-month threshold. For a woman who reaches menopause at 51, postmenopause may represent more than a third of her life. How that life feels, and the long-term health risks she carries, are substantially shaped by how well this stage is understood and managed.
Bleeding after menopause is never normal.
Once you are through menopause, your periods are gone for good, so any vaginal bleeding afterwards, even light spotting, is not a period. Most causes are not serious, but it always needs checking promptly to rule out changes in the lining of the womb, including endometrial cancer, which is very treatable when found early. Do not wait to see whether it settles. Book a review.
Menopause is not the end of something. It is a biological milestone that opens a life stage that deserves every bit as much clinical attention as the decades that came before it.
Making the symptoms make sense.
The symptoms, and the mechanisms behind them.
Not every woman experiences every symptom, and severity varies enormously. Some women find life postmenopause a relief. Others find a new and different set of challenges waiting on the other side. Both experiences are valid, and the range of what is considered normal is wider than most people realise. What follows pairs each common symptom with what is actually driving it, because a mechanism is also a target.
| Symptom | What is happening, and what helps |
|---|---|
| Hot flushes and night sweats | For many women, the vasomotor symptoms that began in perimenopause continue into early postmenopause before gradually diminishing. For some, they can persist for a decade or more. The mechanism is the same: falling oestrogen interferes with the brain’s internal thermostat, causing it to overreact to small rises in body temperature. The result is a sudden wave of heat, flushing, and sweating. At night, this same process can cause drenching sweats that break sleep even when you do not fully wake. Worth knowingFrequency and severity are highly individual. MHT remains the most effective treatment, reducing hot flush frequency by around 75 to 80%. |
| Sleep disturbance | Oestrogen plays a role in serotonin metabolism and the regulation of sleep cycles, so sleep difficulties that began in perimenopause can persist well into postmenopause. Difficulty falling asleep, reduced deep sleep, and early waking are all commonly reported, sometimes even when vasomotor symptoms have settled. Some of this is hormonal, as the loss of progesterone removes one of the body’s natural sleep-supporting signals. But sleep architecture itself also shifts with age, with less restorative deep sleep and more frequent night waking. Poor sleep then drives or worsens many other postmenopausal symptoms, including mood, brain fog, joint pain, and weight changes, in a feedback loop that can be hard to break without targeted support. Worth knowingMHT can improve sleep substantially for many women, particularly when night sweats are part of the picture. Where MHT is not appropriate or not enough, sleep hygiene, cognitive behavioural therapy for insomnia (CBT-I), and short-term melatonin can all play a role. Sleep deserves to be taken as seriously as any other symptom on this list. |
| Mood and emotional wellbeing | For most women, the emotional volatility of perimenopause settles once the hormonal environment stabilises. However, for some, particularly those with a history of mood sensitivity to hormonal change, low mood or anxiety can persist. Worth knowingA new diagnosis of depression in early postmenopause warrants both hormonal and psychiatric consideration. Treating the hormonal component, where present, can substantially improve the psychiatric one. |
| Brain fog and cognitive changes | Cognitive symptoms that began in perimenopause typically improve as hormonal stability returns. Word-finding, concentration, and memory tend to recover. Worth knowingThe evidence suggests these are functional changes related to oestrogen instability, not permanent structural ones, and most women find their mental sharpness returns over time. |
| Joint pain and stiffness | The loss of oestrogen’s anti-inflammatory and collagen-supporting effects can continue to drive joint pain, morning stiffness, and tendon sensitivity in postmenopause. Many women also notice changes in skin texture and elasticity, increased dryness of the skin and mucous membranes, and changes in pelvic floor function as collagen loss accelerates in the early postmenopausal years. Worth knowingFrozen shoulder and lateral epicondylitis (tennis elbow, no court required) can persist into early postmenopause for the same reason. |
| Low libido | Driven by declining testosterone (which continues to fall with age in postmenopause), low oestrogen, and the indirect effects of genitourinary symptoms making sex uncomfortable. Often undertreated because it goes unasked. Worth knowingTestosterone therapy has an evidence base for hypoactive sexual desire disorder in postmenopausal women and is worth raising with your doctor. More on this below. |
Genitourinary syndrome of menopause: its own story.
Why GSM is different.
GSM deserves its own section because it is one of the most common and most undertreated consequences of menopause, and because, unlike vasomotor symptoms, it does not get better on its own. Without treatment, it is progressive, and for many women it quietly and significantly affects quality of life, comfort, and intimacy for years before it is ever addressed.
The vulval, vaginal, and lower urinary tract tissues are richly oestrogen-dependent. They contain more oestrogen receptors per square centimetre than almost anywhere else in the body. As oestrogen declines persistently after menopause, these tissues change: they thin, lose elasticity, and become more vulnerable and fragile. The vaginal pH shifts, altering the local microbiome and increasing susceptibility to infection. The urethral and bladder tissues undergo similar changes.
The symptoms this causes are broad and frequently underreported. Women often do not raise them because they do not know they are treatable, because they feel embarrassed, or because they have been told it is just part of getting older. It is not something that needs to be accepted, and if any of the symptoms below sound familiar, please mention them to your doctor.
The symptoms to look for.
Vaginal: dryness, irritation, burning, discharge, loss of natural lubrication, pain with intercourse (dyspareunia), bleeding after sex, reduced sensation.
Urinary: urgency, frequency, stress incontinence, recurrent urinary tract infections, discomfort passing urine.
Sexual: reduced arousal, difficulty with orgasm, avoidance of intimacy due to discomfort.
What helps.
The first-line treatment for GSM is local (vaginal) oestrogen, available as a cream or pessary. It is delivered directly to the affected tissues with minimal systemic absorption at standard doses. It is safe for long-term use, does not require progesterone cover, and can be used by women who are not using systemic MHT by choice or by circumstance. It can also be added alongside systemic MHT if genitourinary symptoms persist despite adequate systemic therapy.
Prasterone (DHEA) vaginal pessaries are an alternative that works via local conversion to both oestrogen and testosterone within the tissue, with good evidence for painful intercourse and vaginal dryness.
Non-hormonal vaginal moisturisers and vaginal hyaluronic acid pessaries, used regularly (not just during intercourse), can provide useful symptom relief and are appropriate alongside or instead of hormonal options depending on preference and clinical circumstances.
GSM and breast cancer.
Vaginal oestrogen at standard doses does not meaningfully increase systemic oestrogen levels and is not associated with an increased risk of breast cancer. The BMS and most international guidelines support its use even in women with a history of breast cancer, though this should always be discussed with the oncology team. Women on aromatase inhibitors do require specialist input before using vaginal oestrogen, but it is generally considered safe. Please refer to our Breast Health guide for more detail.
Contraception: you are done.
When you can stop.
One of the genuine positives of confirmed menopause: contraception is no longer required. The guidelines are clear. After 12 consecutive months without a period in a woman aged 50 or over, or 24 months in a woman under 50, contraception can be safely stopped.
For women who had a Mirena IUD in place during perimenopause, it can remain as the progestogen component of MHT for five years, even after contraception is no longer needed. For women who are still using the combined oral contraceptive pill (COCP), transitioning to MHT at menopause is a very important conversation. The hormones are the same, but the dose and formulations are significantly different, and MHT provides better symptom management at a much lower risk.
Now, how can we help?
The foundations come first.
So, you have made it through perimenopause, you are 12 months past your last period, and you are wondering what comes next. Where do we go from here? In postmenopause, the conversation about how to manage symptoms and protect long-term health now takes centre stage. That conversation has two parts: the foundations, and the treatments that sit on top of them.
The foundations come first. Nutrition, movement, sleep, stress management, and connection are not optional extras in postmenopause. They are the platform on which everything else sits, and they have real, well-evidenced effects on symptom severity, long-term health, and quality of life.
We know how this lands. “Eat better, sleep more, exercise, manage your stress” is advice every woman has been given a hundred times, often as a substitute for being properly listened to. We get the eye-roll. And yes, we know that it’s not as easy as it sounds. But the evidence really is on the side of the foundations. In many cases they are as effective as, or more effective than, anything we can prescribe. If we could bottle a Mediterranean diet, eight hours of sleep, two resistance sessions, and 50K steps a week, we would. Until then, we are stuck with doing the work. But it is worth doing, and we will help you get started. And because it’s so important, we cover the foundations in detail in a separate guide.
Lifestyle change takes more effort, more time, and more patience than a prescription. In many cases, it is far more powerful.
The hormonal options.
Once the foundations are in place, or at least underway, the conversation about hormonal and non-hormonal support can begin. There is an important principle to understand upfront: women with a uterus need both oestrogen and progesterone. Oestrogen on its own, without progesterone, causes the uterine lining to thicken over time, which increases the risk of endometrial cancer. Progesterone (or a progestogen) is therefore always prescribed alongside oestrogen in women who have a uterus, to protect the lining. Women who have had a hysterectomy do not need progesterone for uterine protection. That said, some women still find benefit from progesterone for sleep, mood, or other symptom reasons. This is off-label use and worth a careful individual risk-benefit discussion.
One important exception. Women who have had a hysterectomy but have a history of endometriosis still need progesterone, because endometriosis tissue sits outside the uterus and remains responsive to oestrogen. In this situation, progesterone protects against the oestrogen feeding any remaining endometrial deposits.
With those principles in mind, here are the hormonal options we most commonly use in postmenopause. Each has a place. The right choice depends on your symptoms, your medical history, and what you are looking for from treatment. MHT is the umbrella term for all of them.
| Option | What it is, and worth knowing |
|---|---|
| Continuous combined MHT: transdermal oestradiol and micronised progesteroneGels: Estrogel, Sandrena. Patches: Estradot, Estraderm MX, Estramon. Body-identical progesterone: Prometrium. | The current first-line recommendation for most postmenopausal women with a uterus and bothersome symptoms. A daily oestradiol patch or gel, taken continuously, with micronised progesterone taken daily to protect the uterine lining and support low-progesterone symptoms. Suits women with vasomotor symptoms, sleep disruption, mood changes, joint pain, and genitourinary symptoms, and those wanting long-term bone and cardiovascular protection. Worth knowingTransdermal oestradiol has a significantly lower clotting risk than oral oestrogen. Micronised progesterone is better tolerated and carries a more favourable breast cancer risk profile than synthetic progestogens. |
| Other forms of combined MHTCombined patches: Estalis Continuous. Oral combined: Bijuva, Femoston Conti, Kliogest. Synthetic progestogen options: Provera, Primolut N. | Not everyone suits or tolerates the same formulation. Other options include combined oestrogen and progestogen patches (both hormones in one patch), oral oestradiol tablets such as Bijuva (which combines oestradiol and progesterone in a single capsule), or oestradiol taken with a synthetic progestogen such as norethisterone or dydrogesterone for women who do not tolerate micronised progesterone. Suits women who have not found the patch or gel agrees with their skin, who prefer a single daily tablet, or who have specific reasons to use a synthetic progestogen. Worth knowingSynthetic progestogens are effective for endometrial protection but carry a higher breast cancer risk profile than micronised progesterone. Oral oestrogen is also not suitable for everyone, as it carries an increased risk of clots. This is worth factoring into the conversation about which formulation is right for you. |
| MHT plus a Mirena IUDTransdermal oestradiol (gel or patch) plus Mirena IUD. | Transdermal oestradiol for systemic symptom control, with the Mirena IUD providing the progesterone component to protect the uterine lining, with minimal systemic progestogen exposure. Suits women who had a Mirena in perimenopause and are continuing into postmenopause, or those who prefer to avoid oral progesterone due to side effects. Worth knowingThe Mirena’s local progestogen delivery means uterine protection with very low systemic progestogen exposure, which suits women who have had tolerability issues with oral progesterone. Most women have no bleeding with this combination. |
| TiboloneLivial. | A synthetic steroid with oestrogen, progesterone, and weak testosterone activity, taken as a single daily tablet. Licensed for use in postmenopausal women only. Good for symptoms and bones, with a low breast risk profile. Especially helpful for low libido, low energy, or mood, and for women who have not found benefit with traditional MHT. Worth knowingTibolone does not stimulate the endometrium and does not require separate progesterone. It has a good evidence base for fracture prevention comparable to standard MHT. It is not recommended in women with a personal history of breast cancer or stroke, and should be used with caution in women who have heart or circulation risk factors, or a history of blood clots. |
| Local (vaginal) oestrogen or DHEAVagifem, Ovestin (vaginal oestrogen). Intrarosa (DHEA pessary). | A low-dose oestrogen preparation (cream or pessary) or DHEA pessary delivered directly to the vaginal and urinary tissues. Covered in detail in the GSM section above. For GSM symptoms: dryness, dyspareunia, urinary urgency, recurrent UTIs. Can be used alone or alongside systemic MHT. Worth knowingMinimal systemic absorption at standard doses. Safe for long-term use without progesterone cover. These symptoms do not improve without treatment and are highly treatable. |
Hormone therapy language.
MHT (menopausal hormone therapy) is now the preferred term over HRT in most current guidelines. The shift in language reflects a shift in approach: supporting a physiological transition with a focus on symptoms and long-term health, rather than simply replacing lost hormones.
You may also encounter the terms natural hormones, bio-identical hormones, and body-identical hormones, often used loosely. Body-identical refers to regulated prescription hormones (like the oestradiol patches and micronised progesterone we have discussed in this guide) that have the same molecular structure as the hormones your body makes itself. Compounded bio-identical hormones, by contrast, are custom-made preparations from compounding pharmacies. They are often marketed as more natural or more personalised, but are not held to the same standards of regulation, dose consistency, quality control, or safety evidence as approved pharmaceutical products. The Australasian Menopause Society (AMS), the RACGP (Royal Australian College of General Practitioners), and Sydney Women’s Wellness do not support their use.
The non-hormonal options.
For women who cannot or prefer not to use hormonal therapy, the non-hormonal toolkit has grown considerably in recent years. None of these options replace MHT for the breadth of effect it offers, but each has an evidence base for specific menopausal symptoms and a place in the right clinical picture.
A relatively new medication developed specifically for hot flushes and night sweats. It works directly on the part of the brain that controls temperature regulation, without touching reproductive hormones. A useful option for women who cannot use hormonal therapy.
Better known as antidepressants, but several of them, paroxetine, escitalopram, and venlafaxine in particular, have good evidence for reducing the frequency and severity of hot flushes. The bonus is that they often help with mood and anxiety changes at the same time, which for many women is part of what makes the symptom load so heavy.
A range of medications that can be used off-label and have evidence for vasomotor symptoms and sleep disruption. They do not work for everyone, but they are worth exploring if MHT is not the right choice for you.
Often overlooked because it is not a tablet, but the evidence here is strong. CBT does not stop hot flushes from happening, but it changes how disruptive they are, and it has good evidence for improving sleep and supporting mood through the transition. A worthwhile option in its own right, or alongside any of the above.
And a word on supplements.
The supplement market aimed at postmenopausal women is enormous, and the quality of evidence behind it varies wildly. There are a few reasons for that. Supplements are not regulated to the same standard as medications. They do not need to prove they work before they can be sold, and the advertising rules they sit under are far looser than the ones applied to anything prescribed. Add to that the fact that supplements are an extremely profitable industry, and you can end up with convincing marketing claims attached to products with very little evidence to back them up.
This is not to say there are no good options out there. There are some supplements with robust evidence behind them, and the picture is easiest to read when sorted by how strong that evidence is.
- Iron, B12, and vitamin D replacing what is deficient, which is more common than most women realise
- Magnesium sleep and muscle symptoms
- Omega-3 most useful where dietary intake of oily fish is low
- Creatine muscle, strength, and cognition
- Vitamin K2 added alongside vitamin D for bone health
- Phytoestrogens hot flushes; found in hops, soy, and flaxseed
- Saffron mood
- Shatavari mood, hot flushes, and libido
We have a separate summary of where the evidence sits for the most commonly asked-about supplements. The most important thing is to bring anything you are considering to your doctor first, to check it is appropriate, evidence-based, and not interacting with anything else you are taking. Some supplements have important interactions with prescription medications, and some are not safe in particular health conditions, even though they are sold without a prescription.
A word on testosterone.
Not a menopause phenomenon.
Testosterone often comes up in conversations about menopause, but it is worth clarifying something important upfront: testosterone decline is not specifically a menopause phenomenon. It is an age-related decline that begins gradually from around the late twenties and continues steadily throughout life. Menopause does not cause a sudden drop in testosterone. However, because testosterone has important effects on energy, mood, cognitive sharpness, muscle mass, bone density, and sexual desire, and because many women in postmenopause are experiencing its sustained decline alongside oestrogen deficiency, it fits naturally into this discussion.
What the evidence supports.
The evidence base for testosterone therapy in postmenopausal women is most robust for hypoactive sexual desire disorder (HSDD), the clinical term for a persistent and distressing loss of sexual desire. Multiple randomised controlled trials and meta-analyses show that testosterone therapy improves sexual desire, arousal, and satisfaction in postmenopausal women, with approximately 50% of women reporting meaningful benefit. Beyond HSDD, women and clinicians frequently report improvements in energy, mood, and cognitive function, though the formal evidence base for these outcomes, while promising, is less established.
Advocates including Professor Louise Newson and the Balance Menopause platform have been instrumental in bringing testosterone’s role in women’s health into broader clinical and public awareness. The anecdotal and clinical experience from practitioners working in this field is compelling and consistent. The formal evidence, much of it led by Australia’s Professor Susan Davis, does not yet support what is seen anecdotally in clinical practice in this area. Whether this is because large enough studies have not been done, or because testosterone has a notable placebo effect, it is still worth discussing the risk versus benefit of a trial of testosterone, especially if low libido, energy, or cognitive fog persist despite adequate oestrogen therapy.
MHT and breast cancer: what the evidence actually shows.
Putting the numbers in context.
This is the question that stops more women from starting MHT than any other. It deserves a proper, honest answer based on the most current evidence available, not the headlines from 2002. The British Menopause Society (BMS) regularly updates its guidance on this topic, and what follows is based on their most recent infographic and fast facts document (2025), alongside the evidence they draw on.
The first and most important thing to understand: most women will not develop breast cancer as a result of taking MHT. The risk, where it exists, is small in absolute terms, and needs to be understood in the context of other factors that affect breast cancer risk, many of which are considerably more significant than MHT.
Breast cancer risk is not a single number. It starts with your own baseline, set mostly by your age, breast density, family history, weight, alcohol intake, smoking, reproductive history, and any previous breast biopsies. MHT can then add a small amount on top, mainly with combined oestrogen and progestogen treatment, and how much depends on how long it is used and which progestogen is chosen.
What this means in practice.
Combined MHT (oestrogen plus a progestogen) is associated with a small increase in breast cancer diagnosis: approximately 4 additional cases per 1,000 women over 5 years. That is the same additional risk as the combined oral contraceptive pill, less than the risk of drinking two or more units of alcohol per day, and considerably less than the risk associated with obesity.
Oestrogen-only MHT, used in women who have had a hysterectomy and do not need progesterone, is associated with 4 fewer cases per 1,000 women compared to the general population. It does not increase breast cancer risk and may actually reduce it.
Seen in proportion, regular exercise lowers this risk by more than combined MHT raises it. That is not an argument against MHT. It is an argument for the whole picture, in which the everyday things within your control weigh as heavily as the decision about hormones.
The type of progestogen matters.
As the chart above shows, the small added risk sits with the older synthetic progestogens rather than with micronised (body-identical) progesterone, which is part of why it is now the preferred form. Our MHT guide works through the formulations in full.
Duration, timing, and mortality.
The risk associated with combined MHT is duration-dependent: the longer it is used, the more cases are observed. However, the BMS is clear that for women at population risk, combined MHT is not associated with an increased risk of breast cancer mortality. In other words, the risk relates to an increase in diagnosis, not in deaths from breast cancer.
Part of the reason for this may be the biology itself, and part may be that women on MHT tend to have more medical contact and more regular breast screening, meaning that any changes are more likely to be detected early. As we know, stage 1 breast cancer is close to 100% survivable. Early detection changes everything. To learn more about breast health and risk, please review our Breast Health guide.
Women at higher risk.
Approximately 90% of women have a low lifetime risk of breast cancer. For most of them, the symptomatic benefits of MHT for up to five years will exceed potential harm. For women with a strong family history, a personal history of high-risk benign breast conditions, or known BRCA mutations, the conversation is more nuanced, but it is definitely worth having. Whether or not a woman can take MHT is never a simple yes or no. It is a personal risk-versus-benefit decision that needs to include consideration of not only breast cancer risk, but bone health, cardiovascular health, and quality of life. All of these carry weight.
This topic needs more than one page.
Breast cancer risk and MHT is one of the most nuanced, frequently misunderstood, and emotionally loaded topics in women’s health. The numbers above are a starting point, not the whole story. Individual risk is shaped by personal and family history, breast density, lifestyle factors, the type and duration of MHT, and much more. Our MHT guide covers this in detail, including how to weigh your personal risk and how to have the conversation with your doctor. We strongly recommend reading it alongside this one.
Long-term health after menopause.
The picture beyond how you feel.
Symptom control matters. Quality of life is not a luxury. But the postmenopausal health picture extends well beyond how you feel day to day. Prolonged oestrogen deficiency has implications for bone health, cardiovascular health, cognitive function, and metabolic health, all of which affect both how long you live and how well you live. The processes that drive these risks begin in the early postmenopausal years. Understanding them is not about creating anxiety. It is about making informed, proactive decisions.
| System | What changes, and what helps |
|---|---|
| Bone health | Oestrogen plays a critical role in regulating bone turnover. In postmenopause, accelerated bone loss of up to 10% in the first five years significantly elevates the risk of osteoporosis and fragility fracture. Hip fracture in particular carries substantial morbidity and mortality. Worth knowingA DEXA scan is recommended for postmenopausal women, particularly those with risk factors including low body weight, smoking, family history, long-term corticosteroid use, or early menopause. FRAX is a calculation used to predict 10-year fracture probability and guide treatment decisions. MHT has a well-established protective effect on bone density, is an approved indication for its use in women at risk, and is a first-line treatment option for osteoporosis. Weight-bearing exercise and adequate calcium and vitamin D are foundational. A DEXA scan and a bone-protection plan are worth discussing with your doctor. |
| Cardiovascular health | Cardiovascular disease is the leading cause of death in postmenopausal women, ahead of all cancers combined. Prior to menopause, oestrogen provides relative cardiovascular protection. After menopause, that protection is gone and risk rises. Worth knowingBaseline cardiovascular risk assessment, blood pressure, lipids, fasting glucose, BMI, smoking status, and family history, should be part of routine postmenopausal care. MHT started within 10 years of menopause or before age 60 (the window of opportunity) appears to reduce cardiovascular disease risk in healthy women. Lifestyle modification, particularly exercise and nutrition, remains the cornerstone of cardiovascular risk reduction at any age. |
| Cognitive health | Oestrogen supports brain health in several important ways, including blood flow to the brain, memory, and the chemical systems that keep thinking clear. Its loss postmenopause is associated with the cognitive symptoms many women experience during the perimenopausal transition. Whether sustained oestrogen deficiency contributes to longer-term dementia risk is an active area of research, with emerging but not yet conclusive evidence. Worth knowingThe cognitive protection piece is promising, but it is not yet a confirmed indication for MHT. Cardiovascular risk reduction protects against vascular dementia. Regular aerobic exercise, cognitive engagement, quality sleep, and social connection all have evidence for supporting long-term cognitive health. |
| Metabolic health | Postmenopause is associated with a shift in fat distribution toward central (abdominal) adiposity, increased insulin resistance, and a more unfavourable lipid profile. These changes elevate the risk of type 2 diabetes and metabolic syndrome. Worth knowingResistance training and aerobic exercise are the most effective interventions for metabolic health in postmenopause. Dietary quality matters significantly. MHT has a modest favourable effect on body composition and insulin sensitivity. The five pillars of wellness are as important here as at any other stage. |
The WHI study: why the fear has been disproportionate.
The wrong women.
If you have read this far and the breast cancer numbers above are reassuring, but a small part of you is still uneasy, this section is for you. That uneasiness usually traces back to one study from 2002, and to the way its findings were reported. Twenty years on, that study still shapes how women, and many clinicians, think about MHT.
The WHI enrolled women with a median age of 63, on average more than 10 years past their last menstrual period. The formulations used were oral conjugated equine oestrogen and medroxyprogesterone acetate, a synthetic progestogen. These are not the formulations recommended first-line in modern MHT practice, where transdermal oestradiol and micronised progesterone are now standard, with a more favourable safety profile. The WHI population bears little resemblance to a healthy woman in her early fifties starting MHT for bothersome symptoms. Starting MHT a decade or more after menopause, in women who may already have underlying cardiovascular changes, is a fundamentally different clinical situation from starting it within the window of opportunity.
The numbers were real, the reporting was not.
The study was halted early due to a reported increase in breast cancer in the combined MHT arm. The reported relative risk was 1.26, which headlines translated as a 26% increased risk of breast cancer. What that figure actually meant was a 26% increase relative to the baseline rate, which in absolute terms amounted to roughly 4 additional cases per 1,000 women over 5 years. The same number sits in the comparison above. It is the comparison points that change everything. Reporting relative risk without the absolute numbers is a well-recognised way of making small risks appear large, and the fear it generated was wildly disproportionate to the actual numbers. Millions of women stopped or never started MHT as a result. The same study, less often quoted, also showed reductions in colorectal cancer and fracture risk in the MHT group.
The reassuring picture since 2002.
The current position of the British Menopause Society, the Australasian Menopause Society, the International Menopause Society, and NICE is clear: for healthy women within 10 years of menopause, the benefits of MHT for symptom control and long-term health outweigh the risks for the majority of women. The decision should be individualised, based on current evidence, and free of the legacy fear generated by a study that does not reflect modern practice.
Large registry studies tracking long-term mortality outcomes in MHT users have not found an association between MHT use and increased all-cause mortality. Some have found a neutral or marginally reduced mortality risk in MHT users, consistent with the window of opportunity.
Armed with the why, now you can ‘hopefully’ sleep at night.
Postmenopause is a significant and, with the right support, hopefully lengthy chapter of a woman’s life. One that carries real health considerations and real opportunities for intervention. The goal is not to fight biology, but to support the body through a transition it was always going to make, and to make the most of the decades that follow.
That means taking symptoms seriously, including the ones that feel embarrassing to raise. It means understanding the long-term stakes around bone, heart, and brain. It means having an honest, evidence-based conversation about MHT, including its benefits, its risks in proper context, and who it is and is not appropriate for. And it means recognising that quality of life in postmenopause is not a luxury consideration. It is a clinical one.
There is something that often gets lost in the medical conversation. Postmenopause, for many women, is also a stage of clarity and focus, free of cycles to manage, contraception to think about, and the hormonal volatility of the years before it. You have spent decades living with a complex hormonal system. You deserve care that understands that system, and supports what comes next. Now that you understand the why, what comes next can be approached with clarity and confidence. And hopefully, a little less Googling at 3am.